Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma ...

Lung cancer remains a leading cause of cancer-related deaths worldwide, demanding focused attention and unwavering commitment ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

Researchers at Mount Sinai have achieved a significant breakthrough in treating hepatocellular carcinoma (HCC), the most ...

Five-year survival rates improved greatly because of immunotherapy and other advances, according to the American Cancer ...